Hyaluronic Acid

Study: A review of real-life setting trials and surveys, published in 2016, evaluating intra-articular hyaluronic acid (IA-HA) for knee osteoarthritis (OA). The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommends IA-HA as a second-line treatment for patients with persistent symptoms despite NSAIDs. The review synthesizes evidence from multiple studies, focusing on pain reduction, functional improvement, and safety.

Findings: IA-HA significantly reduced pain and improved function in knee OA, with benefits lasting up to 40 months after repeated injections. It reduced NSAID use by up to 50% and potentially delayed total knee replacement by about 2 years. The mechanism includes mechanical viscosupplementation and stimulation of endogenous HA production. IA-HA is generally safe, though high molecular weight (HMW) cross-linked formulations may cause more local reactions. Further studies are needed to identify optimal patient profiles.

Study: A 2018 review of 44 prospective clinical trials examining intra-articular and oral HA for knee, hip, and ankle OA. Conducted through PubMed, Ovid, and Web of Science, it assessed efficacy and safety, focusing on pain and function outcomes.

Findings: IA-HA showed varied results, with some trials reporting significant pain relief and functional improvement compared to placebo, particularly for knee OA. Oral HA (decomposed into 2–6 membered polysaccharides) reduced knee pain in a systematic review of 13 trials, with no significant side effects in a 12-month study of 30 patients. Guidelines (OARSI 2012, ACR 2013) neither strongly recommend nor discourage HA due to inconsistent results and large placebo effects. Side effects were minimal, mainly local pain and swelling with injections. Optimal molecular weight, dosage, and injection frequency need further research.

Study: A 2020 pilot RCT in Italy with 60 patients with symptomatic knee OA, comparing oral sodium hyaluronate (FS-HA®) to placebo over 8 weeks. Outcomes included WOMAC scores, Lequesne Functional Index (LFI), Visual Analogue Scale for pain (VAS-p), and knee range of motion (ROM).

Findings: FS-HA significantly improved VAS-p, WOMAC pain and total scores, LFI, and ROM compared to baseline (p < 0.05), with no significant placebo improvements. Patients using FS-HA reduced NSAID/analgesic use. The study suggests oral HA’s anti-inflammatory effects via Toll-like receptor-4 binding, promoting IL-10 and cytokine signaling. No significant side effects were reported, supporting oral HA’s safety.

Study: A 2015 meta-analysis of RCTs with low risk of bias, focusing on IA-HA for knee OA. It included trials with at least three weekly injections, intra-articular placebo controls, and validated pain assessment scales, analyzing pain reduction at 2–3 months.

Findings: Across 22 trials (2,949 knees), IA-HA showed a modest pain reduction effect size (0.32), reduced to 0.19 after excluding outliers. Intra-articular placebo accounted for 79% of the effect, indicating a strong placebo response. Significant publication bias was noted, with 17 of 22 studies industry-sponsored. Higher molecular weight HA showed larger effect sizes, but overall efficacy was limited compared to NSAIDs or corticosteroids.

Study: A 2012 RCT with 426 patients with symptomatic knee OA, comparing intermediate molecular weight HA (GO-ON, 800–1500 kD) to low molecular weight HA (Hyalgan, 500–730 kD) over 6 months. Patients received three weekly injections, with WOMAC pain subscale as the primary outcome.

Findings: GO-ON was non-inferior and slightly superior to Hyalgan in reducing pain (WOMAC pain score improvement: 21.4 mm vs. 18.4 mm). OARSI-OMERACT responder rates were higher for GO-ON. Both treatments were well-tolerated, with minor local reactions. Intermediate molecular weight HA may offer better efficacy, but further studies are needed to confirm.

Study: A 2022 meta-analysis of RCTs from 1970–2021, including patients with confirmed knee OA, comparing IA-HA to placebo or no intervention. It assessed pain, function, and serious adverse events using data from Medline, Embase, and CENTRAL.

Findings: IA-HA provided negligible pain relief and functional improvement compared to placebo, with a high placebo effect. Approximately 28% of Medicare costs for viscosupplementation were linked to treating joint infections. The study concluded that IA-HA offers minimal clinical benefit and potential risks, questioning its widespread use. Guidelines (e.g., NICE, AAOS) increasingly discourage IA-HA due to limited efficacy.

Study: A study (date not specified) evaluating glucosamine combined with sodium hyaluronate versus glucosamine alone for osteoporosis with knee OA. Outcomes included pain relief, joint function, and bone metabolic markers.

Findings: The combination of glucosamine and sodium hyaluronate was superior to glucosamine alone in reducing pain and improving joint function in patients with osteoporosis and knee OA. The study did not isolate HA’s specific effects, limiting conclusions about HA alone. No serious side effects were reported.